Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma

Riten Kumar; Paul J. Galardy; Ahmet Dogan; Vilmarie Rodriguez; Shakila P. Khan

doi:10.1002/pbc.23110

Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma

Riten Kumar, Paul J. Galardy, Ahmet Dogan, Vilmarie Rodriguez, Shakila P. Khan

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Given the rarity of follicular lymphoma (FL) in children, there is limited data on which to base treatment recommendations. Herein, we report our institutional experience of using rituximab with multiagent chemotherapy for pediatric FL. Six pediatric patients were diagnosed with FL from 2000 to 2009. All patients received rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for varying durations. Five of the six patients remain in remission with a median follow-up of 31 months. Larger randomized trials are indicated to establish the efficacy of this regimen for pediatric FL patients.

Original language	English (US)
Pages (from-to)	317-320
Number of pages	4
Journal	Pediatric Blood and Cancer
Volume	57
Issue number	2
DOIs	https://doi.org/10.1002/pbc.23110
State	Published - Aug 2011

Keywords

Follicular lymphoma
Rituximab

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.23110

Cite this

@article{85c0fb148fd0490d8e747688f1c9c38a,

title = "Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma",

abstract = "Given the rarity of follicular lymphoma (FL) in children, there is limited data on which to base treatment recommendations. Herein, we report our institutional experience of using rituximab with multiagent chemotherapy for pediatric FL. Six pediatric patients were diagnosed with FL from 2000 to 2009. All patients received rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for varying durations. Five of the six patients remain in remission with a median follow-up of 31 months. Larger randomized trials are indicated to establish the efficacy of this regimen for pediatric FL patients.",

keywords = "Follicular lymphoma, Rituximab",

author = "Riten Kumar and Galardy, {Paul J.} and Ahmet Dogan and Vilmarie Rodriguez and Khan, {Shakila P.}",

year = "2011",

month = aug,

doi = "10.1002/pbc.23110",

language = "English (US)",

volume = "57",

pages = "317--320",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma

AU - Kumar, Riten

AU - Galardy, Paul J.

AU - Dogan, Ahmet

AU - Rodriguez, Vilmarie

AU - Khan, Shakila P.

PY - 2011/8

Y1 - 2011/8

N2 - Given the rarity of follicular lymphoma (FL) in children, there is limited data on which to base treatment recommendations. Herein, we report our institutional experience of using rituximab with multiagent chemotherapy for pediatric FL. Six pediatric patients were diagnosed with FL from 2000 to 2009. All patients received rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for varying durations. Five of the six patients remain in remission with a median follow-up of 31 months. Larger randomized trials are indicated to establish the efficacy of this regimen for pediatric FL patients.

AB - Given the rarity of follicular lymphoma (FL) in children, there is limited data on which to base treatment recommendations. Herein, we report our institutional experience of using rituximab with multiagent chemotherapy for pediatric FL. Six pediatric patients were diagnosed with FL from 2000 to 2009. All patients received rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for varying durations. Five of the six patients remain in remission with a median follow-up of 31 months. Larger randomized trials are indicated to establish the efficacy of this regimen for pediatric FL patients.

KW - Follicular lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=79958782287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958782287&partnerID=8YFLogxK

U2 - 10.1002/pbc.23110

DO - 10.1002/pbc.23110

M3 - Article

C2 - 21462303

AN - SCOPUS:79958782287

SN - 1545-5009

VL - 57

SP - 317

EP - 320

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 2

ER -

Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this